The conflict in the Ukraine is the first war in a fully interconnected world, wired more closely than ever before by trade, supply chains and financial markets. As such, while the drama is occurring within Ukraine’s frontiers, the consequences of Putin’s “special military operation” are being felt across the globe. The US (and pending European) decision to ban Russian oil imports has fueled the commodity rally, playing into worries over global supplies and heightening stagflation concerns. Central banks, however, are still intent on normalising policy. The Fed has initiated its tightening cycle with a 25 bps hike and signaled six further increases in 2022, for what would be the most aggressive policy campaign in decades. And an announcement regarding balance sheet reduction could come as soon as May.
We attended the ASCO 2023 annual meeting in Chicago. After the rise of immuno-oncology, COVID-19 challenged clinical trial execution and muted patient numbers. In the last years we saw many setbacks of once promising immuno-oncology combinations trials.
What mattered this month in healthcare? Q1 reporting came to a close, and FTC action put pressure on the biopharma space and... Find out more in our monthly healthcare newsletter.
With M&A picking up, are we at a turning point for biotech? Check out our latest Kieger AG Chart of the Month Video.